Cerebrolysin
Cerebrolysin is a porcine-brain-derived mixture of peptides and amino acids. In CASTA, the confirmatory combined functional outcome after acute ischemic stroke was neutral.
Research topics
Read the studies →
EXPLORE THE BIOLOGY
Content updated · how dates work
Neurobiology, cognition, and anxiety research.
This topic groups related research questions. Shared biology does not make different peptides interchangeable, or establish a clinical benefit. Compare each paper’s population, preparation, and measured outcome.
Each peptide is sorted by the strongest kind of human study among its profile’s selected studies, and the row shows what that study found and who was studied. A higher tier means stronger evidence exists, not that the peptide works for brain & mood: the best trial may be small, negative or about a different condition. No doses.
| Peptide | Strongest human evidence in our sources | FDA | Human safety data |
|---|---|---|---|
| FDA-approved medicine (2)Approved for the specific uses on its label, which may not be this goal. | |||
| Lixisenatide | ELIXA (2015) · Human randomized trial The primary cardiovascular composite occurred in 13.4% with lixisenatide and 13.2% with placebo: hazard ratio 1.02 (95% CI 0.89–1.17). Noninferiority was established; superiority was not. Limitation: The finding supports cardiovascular safety within the trial’s prespecified framework. It does not establish cardiovascular benefit. Heart-failure hospitalization and mortality were not significantly different. Sanofi funded the trial. Studied: 6,068 people with type 2 diabetes and an acute coronary event in the preceding 180 days. | FDA-approved | FDA label |
| Ziconotide | Ziconotide refractory-pain randomized trial (2004) · Human randomized trial Mean visual-analog pain-intensity improvement was 53.1% with ziconotide versus 18.1% with placebo. Limitation: The study was short and examined a specialized delivery route in a severely affected population. It cannot establish long-term benefit-risk or a general injury-recovery use. Studied: 111 patients with refractory pain due to cancer or AIDS, studied at 32 centers. | FDA-approved | FDA label |
| Randomized human trials (3)At least one randomized or placebo-controlled trial, which may be small, negative or about another condition. | |||
| Cerebrolysin | CASTA acute ischemic stroke trial (2012) · Human randomized trial The confirmatory combined functional endpoint did not show a significant benefit. A post-hoc analysis suggested a signal in more severely affected participants. Limitation: A subgroup signal following a neutral primary result needs confirmation; it should not be substituted for the main trial outcome. Studied: 1,070 patients with acute ischemic stroke. | Not approved | Trials only |
| PACAP-38 | PACAP-38 challenge after eptinezumab or placebo (2025) · Human randomized provocation study Migraine occurred in 10 of 19 versus 12 of 19 participants; the difference was not significant (P=0.74). Headache was common after the challenge. Limitation: The small provocation study does not establish therapeutic benefit of PACAP-38 or a definitive clinical prevention strategy. Studied: 38 participants with migraine without aura, 19 in each pretreatment group. | Not approved | Trials only |
| TRH (thyrotropin-releasing hormone) | TRH for cancer-related fatigue (2012) · Human randomized crossover pilot trial Energy ratings and the fatigue and vigor scores improved with TRH compared with placebo, along with fatigue-related quality of life. TRH caused brief rises in blood pressure and heart rate. Limitation: Only eight patients completed the study, effects were measured over hours to a day, and no larger trial has confirmed the result. It does not show benefit for fatigue in people without cancer or with longer use. Studied: Eight adults with cancer and significant fatigue without a reversible medical cause. | Withdrawn | Trials only |
| Small or uncontrolled human studies (3)Human reports without randomization, such as pilots, case series or open-label studies. | |||
| DSIP | Chronic insomnia experiment (1992) · Small blinded human study Some objective sleep measures changed modestly, but subjective sleep quality did not improve. The authors considered major short-term therapeutic benefit unlikely. Limitation: The small sample, short duration, and partly placebo-driven differences limit confidence. The name “delta sleep-inducing peptide” is not itself evidence of an insomnia treatment. Studied: 16 people with chronic insomnia. | Not approved | Very limited |
| Selank | Anxiety-disorder comparison (2014) · Small human comparative study The authors reported anxiety improvement, tolerability, and quality-of-life findings, including effects persisting a week after treatment. Limitation: The abstract does not adequately resolve allocation, blinding, effect size, or long-term harms. It is not a placebo-controlled replication or proof of routine effectiveness across anxiety disorders. Studied: 60 patients with phobic-anxiety or somatoform disorders. | Not approved | Very limited |
| Semax | Semax · early clinical stroke report (1997) · Human comparative study The authors reported faster regression of neurological deficits, especially motor impairment, with added Semax; numerical treatment effects and confidence intervals are not provided. Limitation: Unequal groups, unclear allocation, and limited reporting leave substantial uncertainty. The Russian-language methods require review. Acute stroke findings cannot establish memory enhancement in healthy people or modern clinical practice recommendations. Studied: 30 treated patients with acute hemispheric ischemic stroke and 80 controls described as having comparable lesion location and severity. | Not approved | Very limited |
| Animal and lab studies only (13)No human study in our sources. | |||
| Cortistatin | See the profile for the animal and lab research. | Not approved | None |
| Dihexa | See the profile for the animal and lab research. | Not approved | None |
| GHK | See the profile for the animal and lab research. | Not approved | None |
| Humanin | See the profile for the animal and lab research. | Not approved | None |
| IGF-1 DES | See the profile for the animal and lab research. | Not approved | None |
| N-Acetyl Selank | See the profile for the animal and lab research. | Not approved | None |
| NA-Semax Amidate | See the profile for the animal and lab research. | Not approved | None |
| Nesfatin-1 | See the profile for the animal and lab research. | Not approved | None |
| Neuropeptide Y | See the profile for the animal and lab research. | Not approved | Very limited |
| Orexin-A | See the profile for the animal and lab research. | Not approved | Very limited |
| P21 | See the profile for the animal and lab research. | Not approved | None |
| PE-22-28 | See the profile for the animal and lab research. | Not approved | None |
| Pinealon | See the profile for the animal and lab research. | Not approved | Very limited |
Selected studies, not a systematic review. Approval belongs to a specific product and use. Side-by-side comparisons: Selank vs Semax · Epitalon vs Pinealon (all comparisons).
Cerebrolysin is a porcine-brain-derived mixture of peptides and amino acids. In CASTA, the confirmatory combined functional outcome after acute ischemic stroke was neutral.
Research topics
Read the studies →Cortistatin is a neuropeptide family investigated in inflammatory signaling. The selected study used a mouse arthritis model rather than people with rheumatoid arthritis.
Research topics
Read the studies →Dihexa is a small angiotensin IV–derived peptidomimetic (a two-amino-acid core with chemical caps) developed at Washington State University and sold online as a cognitive enhancer. The evidence is from rodent and cell studies. Its main mechanism paper was retracted in 2025, the original paper carries a 2021 expression of concern, and no human study has been published.
Research topics
Read the studies →DSIP stands for delta sleep-inducing peptide. The name reflects its research history, while actual sleep outcomes require direct measurement.
Research topics
Read the studies →GHK is the Gly-His-Lys tripeptide. It is distinct from GHK-Cu, its copper complex. The selected study examined anxiety-like behavior in male rats.
Research topics
Read the studies →Humanin emerged from experiments examining neuronal cell survival. It is a research topic in mitochondrial and neurodegenerative biology, not an established dementia treatment.
Research topics
Read the studies →Des(1-3) IGF-1 is an IGF-1 analogue missing its first three amino acids. The featured study examined developing rat neural tissue in culture, rather than athletic performance.
Research topics
Read the studies →Lixisenatide is a GLP-1 receptor agonist. ELIXA studied cardiovascular safety in people with type 2 diabetes who had recently experienced an acute coronary event.
Research topics
Read the studies →N-Acetyl Selank is a modified Selank label. The selected clinical report studied parent Selank, not a verified N-acetylated variant; its findings are included as related background.
Research topics
Read the studies →NA-Semax Amidate describes a Semax variant with terminal modifications. The selected laboratory publication examined acetylated Semax, but does not verify the complete marketed acetylated-and-amidated variant.
Research topics
Read the studies →Nesfatin-1 is a NUCB2-derived peptide investigated in feeding regulation. Its foundational evidence involved central administration and signaling experiments in rats.
Research topics
Read the studies →Neuropeptide Y is an endogenous signaling peptide involved in feeding circuitry. The selected mouse study examined NPY-related neurons and feeding behavior rather than a clinical peptide treatment.
Research topics
Read the studies →Orexin-A, also known as hypocretin-1, is a hypothalamic signaling peptide. The foundational paper identified orexin peptides and receptors and studied feeding responses in rats.
Research topics
Read the studies →P21 is a research-market label that needs sequence confirmation. The selected paper studied the CNTF-derived candidate P021; it is presented as related research rather than proof that every product labeled P21 has that identity.
Research topics
Read the studies →PACAP-38 is a signaling peptide used in migraine-provocation research. The selected clinical study tested whether prior CGRP-pathway treatment prevented a migraine response to a PACAP-38 challenge.
Research topics
Read the studies →PE-22-28 is a seven-amino-acid peptide designed from spadin, a naturally occurring fragment of the sortilin propeptide. Its published evidence comes from cell-channel experiments and mouse behavior tests, not studies in people.
Research topics
Read the studies →Pinealon is a tripeptide investigated in experimental stress-response biology. The selected publication concerns cells under oxidative stress, rather than a clinical memory or dementia trial.
Research topics
Read the studies →Selank is a research peptide discussed for anxiety-related effects. Its small clinical literature needs careful attention to study design and replication.
Research topics
Read the studies →Semax is a seven-amino-acid peptide investigated in neurobiological research. The selected study examines responses to experimental brain ischemia.
Research topics
Read the studies →TRH is one of the body's own hormones: a tiny peptide made in the brain that tells the pituitary gland to release thyroid-stimulating hormone. A synthetic version, protirelin, was long used in a hospital test of thyroid and pituitary function. Researchers have also studied it in small trials for fatigue, depression and nerve diseases.
Research topics
Read the studies →Ziconotide is a venom-derived peptide medicine that blocks N-type calcium channels. Its pain research concerns specialist intrathecal delivery, not a generic injectable recovery peptide.
Prescription medicines
Read the studies →See something wrong on this page? Report a mistake · Corrections